15.04.2024 Nynomic AG  DE000A0MSN11

Original-Research: Nynomic AG (von NuWays AG): Kaufen


Original-Research: Nynomic AG - from NuWays AG

Classification of NuWays AG to Nynomic AG

Company Name: Nynomic AG

Reason for the research: Update
Recommendation: Kaufen
from: 15.04.2024
Target price: EUR 52.00
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Christian Sandherr

New product launched: Another building block for the mid-term

Nynomic announced that its subsidiary Spectral Engines and Kraemer Elektronik, an expert for high quality testing systems of bulk solids for the pharmaceutical, chemical and food industry, have jointly developed and now presented a new product, the LabScanner Plus.

While Kraemer Elektronik provides the casing including the technology to measure weight and shape, Nynomic’s eight sensors (based on the NIRONE scanner) quickly determine the composition of the tested pills. With this, one can analyze and digitalize the results of large sample sizes quickly. Originally intended to quickly build up the databases necessary to reliably detect counterfeit pharmaceuticals with its handheld sensors, it should be met with broad interest from quality assurance departments in the pharmaceutical industry.

Following the successful certification from potential customers, Nynomic should be able to generate first sales this year already, eNuW. While we only expect a small sales contribution from LabScanner Plus in FY24e (~ € 1m, eNuW), it contributes another building block to management’s mid- to long-term strategy and should have the potential for a mid single-digit annual sales contribution during the next few years.

FY24 growth to accelerate. Following last year’s muted sales growth (1%) largely due to the lumpy nature of parts of the group and customers’ inventory normalizations, FY24e looks set to show a notable acceleration. We expect 12% yoy growth (8% organic) on the back of a number of drivers including (1) unbroken demand from semi customers, (2) fulfilment precision farming orders, (3) TactiScan gaining traction, (4) a structurally growing medtech market and (5) new product launches such as LabScanner Plus.

Additional growth from acquisitions likely. As highlighted during the recent earnings call and inline with the growth strategy, Nynomic should be looking to add 1-2 additional companies during the next six months. Thanks to its balance sheet strength, it could also consider larger targets with up to € 20m sales. Trading below 11x EV/EBIT FY24e and in light of the prospects reflected in the company's mid-term guidance of € 200m sales and a 16-19% EBIT margin, shares look attractively priced. We confirm our BUY rating with an unchanged € 52 PT based on DCF.

You can download the research here:
For additional information visit our website www.nuways-ag.com/research.

Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++

-------------------transmitted by EQS Group AG.-------------------

The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 60,69 68,90 64,86 78,56 105,08 116,79 117,99
EBITDA1,2 10,18 13,24 9,55 11,43 17,00 19,18 20,22
EBITDA-Marge3 16,77 19,22 14,72 14,55 16,18 16,42
EBIT1,4 9,12 11,87 6,43 7,97 12,99 15,08 15,43
EBIT-Marge5 15,03 17,23 9,91 10,15 12,36 12,91 13,08
Jahresüberschuss1 6,07 9,35 4,30 5,18 9,52 9,95 10,53
Netto-Marge6 10,00 13,57 6,63 6,59 9,06 8,52 8,93
Cashflow1,7 9,00 2,18 3,56 6,37 17,83 9,68 3,17
Ergebnis je Aktie8 0,97 1,71 0,87 0,83 1,37 1,26 1,47
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Dr. Clauß, Dr. Paal & Partner

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0MSN1 29,300 Kaufen 192,10
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
16,28 21,19 0,60 29,36
1,94 60,68 1,63 9,65
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
0,00 0,00 0,00 02.07.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2024 30.08.2024 29.11.2024 22.05.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,90% -7,92% -7,86% -14,83%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Nynomic AG  ISIN: DE000A0MSN11 können Sie bei EQS abrufen

Elektrotechnik , A0MSN1 , M7U , XETR:M7U